BRPI0415434A - compostos e métodos para tratar e prevenir arritmias cardìacas induzidas por exercìcios - Google Patents

compostos e métodos para tratar e prevenir arritmias cardìacas induzidas por exercìcios

Info

Publication number
BRPI0415434A
BRPI0415434A BRPI0415434-7A BRPI0415434A BRPI0415434A BR PI0415434 A BRPI0415434 A BR PI0415434A BR PI0415434 A BRPI0415434 A BR PI0415434A BR PI0415434 A BRPI0415434 A BR PI0415434A
Authority
BR
Brazil
Prior art keywords
methods
preventing
induced
exercise
treating
Prior art date
Application number
BRPI0415434-7A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shi Xian Deng
Zhen Zhuang Cheng
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of BRPI0415434A publication Critical patent/BRPI0415434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/326—Arrhythmias, e.g. ventricular fibrillation, tachycardia, atrioventricular block, torsade de pointes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

"COMPOSTOS E MéTODOS PARA TRATAR E PREVENIR ARRITMIAS CARDìACAS INDUZIDAS POR EXERCìCIOS". A presente invenção refere-se a um método para limitar ou prevenir uma diminuição no nível de FKBP12.6 ligado a RyR2 em um indivíduo, um método para tratar ou prevenir a arritmia cardíaca induzida por exercícios em um indivíduo, e um método para prevenir a morte cardíaca súbita induzida por exercícios em um indivíduo. Também são oferecidos os usos de JTV-519 nesses métodos. A presente invenção refere-se ainda métodos para identificar agentes para uso na prevenção de morte cardiaca súbita induzida por exercícios, bem como agentes identificados por tais métodos. Também são fornecidos métodos para prevenir a morte cardíaca súbita induzida por exercícios pela administração desses compostos. Além disso, a presente invenção fornece métodos para sintetizar JTV-519, JTV-519 radiomarcado, e intermediários e derivados de 1,4-benzotiazepina.
BRPI0415434-7A 2003-10-07 2004-10-04 compostos e métodos para tratar e prevenir arritmias cardìacas induzidas por exercìcios BRPI0415434A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/680,988 US20040229781A1 (en) 2000-05-10 2003-10-07 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
PCT/US2004/032550 WO2005037195A2 (en) 2003-10-07 2004-10-04 Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias

Publications (1)

Publication Number Publication Date
BRPI0415434A true BRPI0415434A (pt) 2006-12-05

Family

ID=34465444

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415434-7A BRPI0415434A (pt) 2003-10-07 2004-10-04 compostos e métodos para tratar e prevenir arritmias cardìacas induzidas por exercìcios

Country Status (14)

Country Link
US (1) US20040229781A1 (pt)
EP (1) EP1684735A4 (pt)
JP (1) JP2007507536A (pt)
KR (1) KR20060110290A (pt)
CN (1) CN100502845C (pt)
AU (1) AU2004281672A1 (pt)
BR (1) BRPI0415434A (pt)
CA (1) CA2541847A1 (pt)
EA (1) EA011357B1 (pt)
MA (1) MA28146A1 (pt)
NO (1) NO20062063L (pt)
SG (1) SG147414A1 (pt)
WO (1) WO2005037195A2 (pt)
ZA (1) ZA200603593B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20070264319A1 (en) * 2004-09-01 2007-11-15 Lebo David B Transdermal Antiemesis Delivery System, Method and Composition Therefor
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008140592A2 (en) * 2006-11-29 2008-11-20 Armgo Pharma, Inc. Radioactively labeled 1,4-benzothiazepines and methods of screening for compounds that bind ryanodine receptors
US8618282B2 (en) * 2008-03-03 2013-12-31 Les Laboratoires Servier Process for preparing benzothiazepines from gamma-aminoalkylbenzenes
US8933129B2 (en) 2009-04-15 2015-01-13 State Of Oregon By And Through The State Board Of Higher Education On Behalf Of Portland State University Compounds and methods for modulating activity of calcium release channels
EP2708535A1 (en) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
WO2023091524A1 (en) * 2021-11-16 2023-05-25 Armgo Pharma, Inc. Therapeutic compounds

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) * 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
EP0150996B1 (en) * 1984-01-27 1988-01-07 Ajinomoto Co., Inc. Manufacture of heptanoic acid derivatives
US4841055A (en) * 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
US4723012A (en) * 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US6956032B1 (en) * 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5124056A (en) * 1987-07-24 1992-06-23 Exxon Chemical Patents Inc. Polymer substituted amido-amine Mannich Base lubricant dispersant additives
JPS6445706A (en) * 1987-08-17 1989-02-20 Sumitomo Electric Industries Production of composite carbon nitride
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) * 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
US5223508A (en) * 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
EP0446374B1 (en) * 1989-09-30 1996-02-07 Kirin Beer Kabushiki Kaisha Method of producing seedling
KR940000166B1 (ko) * 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US5204462A (en) * 1990-03-30 1993-04-20 Japan Tobacco, Inc. 4h-3,1-benzoxazin-4-one derivative
US5517652A (en) * 1990-05-30 1996-05-14 Hitachi, Ltd. Multi-media server for treating multi-media information and communication system empolying the multi-media server
JP2651043B2 (ja) * 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) * 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5180720A (en) * 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5182272A (en) * 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
AU3143593A (en) * 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) * 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
US5387684A (en) * 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
US5304644A (en) * 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
CA2139362A1 (en) * 1992-07-02 1994-01-20 Kooji Kagara Novel intermediate for synthesis and production of amino acid derivative
EP0656356A1 (en) * 1992-08-21 1995-06-07 Japan Tobacco Inc. Dioxacycloalkane compound with renin-inhibiting activity
ES2113081T3 (es) * 1992-11-09 1998-04-16 Knoll Ag 1,4-benzotiazepinas utiles como agentes neurologicos.
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
CA2153498A1 (en) * 1993-11-10 1995-05-18 Hidetsura Cho Chroman derivative and medicinal use thereof
JPH08127594A (ja) * 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
US6897295B1 (en) * 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JP3914272B2 (ja) * 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) * 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
DE69535865D1 (de) * 1994-06-15 2008-11-27 Kirin Brewery Transferase und Amylase, Verfahren zur Herstellung dieser Enzyme, ihre Verwendung und kodierende Gene
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) * 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US5906819A (en) * 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
KR100860655B1 (ko) * 1996-07-08 2008-09-26 기린 파마 가부시끼가이샤 칼슘 수용체 활성 화합물
US5785178A (en) * 1996-11-04 1998-07-28 Minnesota Mining And Manufacturing Co. Packaged photocurable composition
US6338955B2 (en) * 1996-12-12 2002-01-15 Kirin Beer Kabushiki Kaisha β1-4 N-acetylglucosaminyltransferase and gene encoding
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
CA2274776C (en) * 1997-10-08 2008-11-25 Noboru Kaneko Method for analyzing annexin v in urine and use thereof
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
EP1043335A4 (en) * 1997-12-25 2005-08-31 Japan Tobacco Inc MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS MEDICAL APPLICATIONS
RU2202344C2 (ru) * 1998-03-26 2003-04-20 Джапан Тобакко Инк. Антагонисты ноцицептина, производные амида, аналгетик, способ инициирования антагонистического действия к ноцицептину, способ лечения боли, фармацевтические композиции
IL138899A0 (en) * 1998-04-10 2001-11-25 Japan Tobacco Inc Amidene derivatives and pharmaceutical compositions containing the same
WO1999064045A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel therapeutic agents for membrane transporters
US6890531B1 (en) * 1998-07-31 2005-05-10 Kirin Beer Kabushiki Kaisha Neuronal growth factor galectin-1
ATE314852T1 (de) * 1998-12-28 2006-02-15 Noboru Kaneko Verwendung von 1,4-benzothiazepinen zur herstellung eines medikaments zur behandlung der vorhof-fibrillation
CA2368734C (en) * 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
AU7097400A (en) * 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
ATE359788T1 (de) * 1999-09-30 2007-05-15 Noboru Kaneko Verwendung von diphenylmethylpiperazin-derivaten zur herstellung eines medikaments zur unterdrückung der proliferation von fibroblasten
US6568474B2 (en) * 1999-12-20 2003-05-27 Bj Services, Usa Rigless one-trip perforation and gravel pack system and method
JP2003518494A (ja) * 1999-12-29 2003-06-10 グラクソ グループ リミテッド アネキシンおよび軟骨ホメオスタシスのモジュレーターに関係する方法と組成物
HUP0204071A3 (en) * 2000-01-20 2003-07-28 Eisai Co Ltd Nitrogenous cyclic compounds and pharmaceutical compositions containing the same and their use
US6545170B2 (en) * 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
EP1280555B8 (en) * 2000-05-03 2006-06-28 Astellas Pharma Inc. Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
ES2281431T3 (es) * 2000-07-27 2007-10-01 Pharmacia Corporation Terapia de combinacion con antagonista epoxi-esteroidal de aldosterona y bloqueador de los canales de calcio para tratamiento de la insuficiencia cardiaca congestiva.
MY131964A (en) * 2000-09-15 2007-09-28 Pharmacia Corp 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
AR031129A1 (es) * 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
MXPA03004793A (es) * 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US6673904B2 (en) * 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
JPWO2002061076A1 (ja) * 2001-02-01 2004-06-03 持田製薬株式会社 アディポネクチン関連蛋白質
JP4817514B2 (ja) * 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
JP4175113B2 (ja) * 2001-03-14 2008-11-05 小野薬品工業株式会社 Ｅｐ１アンタゴニストを有効成分として含有するうつ病の治療剤
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
MXPA03009662A (es) * 2001-04-27 2004-12-06 Kirin Brewery Derivados de quinolina y derivados de quinazolina que tienen grupos azolilo.
WO2003024395A2 (en) * 2001-09-14 2003-03-27 Tularik Inc. Linked biaryl compounds
JP2003145746A (ja) * 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
US20060100195A1 (en) * 2001-11-19 2006-05-11 Takayuki Maruyama Remedies for urinary frequency
AU2002349705A1 (en) * 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
CA2471639A1 (en) * 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
AU2003227433A1 (en) * 2002-04-26 2003-11-10 Japan Tobacco Inc. Bar-like article forming device
JP4113042B2 (ja) * 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
CN1289467C (zh) * 2002-08-30 2006-12-13 日本烟草产业株式会社 二苄胺化合物及其药物用途
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
WO2004093896A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20050070543A1 (en) * 2003-07-11 2005-03-31 Pharmacia Corporation Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
JP2007501801A (ja) * 2003-08-07 2007-02-01 日本たばこ産業株式会社 ピロロ［１，２−ｂ］ピリダジン誘導体
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005023182A2 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2005104835A2 (en) * 2004-04-22 2005-11-10 Kirin Beer Kabushiki Kaisha Transgenic animals and uses thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) * 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
RU2392278C2 (ru) * 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
KR20060110290A (ko) 2006-10-24
EA200600740A1 (ru) 2006-10-27
EP1684735A4 (en) 2009-01-07
US20040229781A1 (en) 2004-11-18
SG147414A1 (en) 2008-11-28
CA2541847A1 (en) 2005-04-28
CN100502845C (zh) 2009-06-24
NO20062063L (no) 2006-07-07
WO2005037195A2 (en) 2005-04-28
CN1886122A (zh) 2006-12-27
MA28146A1 (fr) 2006-09-01
WO2005037195A3 (en) 2005-12-01
ZA200603593B (en) 2010-10-27
EP1684735A2 (en) 2006-08-02
AU2004281672A1 (en) 2005-04-28
EA011357B1 (ru) 2009-02-27
JP2007507536A (ja) 2007-03-29

Similar Documents

Publication Publication Date Title
NO20062063L (no) Forbindelser og fremgangsmater for behandling og forbyggelse av treningsinduserte hjerte arrytmier
EA200702057A1 (ru) Новые антиаритмические и применяемые при сердечной недостаточности лекарственные средства, которые направлены против "просачивания" рецептора рианодина (ryr2)
GT200600134A (es) Compuestos novedosos de derivados de aminosulfonilo
EA200601765A1 (ru) Новые антиаритмические лекарственные средства и лекарственные средства, применяемые при сердечной недостаточности, нацеленные на утечку в рецепторе рианодина (ryr2), и их применение
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
PA8491901A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
BR0113039A (pt) Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
EP1532269A4 (en) 1L1RL-1 AS A MARKER OF CARDIOVASCULAR DISEASES AND THERAPEUTIC TARGET
NO20024424L (no) Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater tilfremstilling av derivatene
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0416212A (pt) derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação
BR0206496A (pt) Diaminotiazóis
PA8558001A1 (es) Derivados de isonicotin y nicotinamida de benzotiazoles
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
DE602005007769D1 (de) Neue derivate von porphyrin, insbesondere chlorine und bacteriochlorine und ihre verwendungen in der photodynamischen therapie
BRPI0406646A (pt) Compostos de(2-carboxamido)(3-amina)tiofenos, bem como composições e usos compreendendo os mesmos
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BR9809598A (pt) Uso de compostos, e, composto.
PE20010751A1 (es) Quinolin-2-ona como inhibidores de las proteinas resistentes a multiples farmacos
BR0308144A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.